Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 26.99
- Piotroski Score 2.00
- Grade Market Outperform
- Symbol (BNTC)
- Company Benitec Biopharma Inc.
- Price $10.47
- Changes Percentage (2.68%)
- Change $0.27
- Day Low $9.88
- Day High $10.49
- Year High $12.89
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
- Last Earnings 05/25/2018
- Ex-Dividend for 5/16 Dividend 06/01/2018
- Dividend Payable 06/08/2018
- Today N/A
- Next Earnings (Estimated) 02/10/2025
- Fiscal Year End N/A
- Average Stock Price Target $18.00
- High Stock Price Target $30.00
- Low Stock Price Target $13.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$235.52
- Trailing P/E Ratio -0.03
- Forward P/E Ratio -0.03
- P/E Growth -0.03
- Net Income $-21,751,000
Income Statement
Quarterly
Annual
Latest News of BNTC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans
Benitec Biopharma's stock has surged 205%, despite being a loss-making company. Analyzing its cash burn rate and runway, it seems relatively promising. However, potential dilution and risks should be ...
By Yahoo! Finance | 1 month ago
